C07K 14/5437
Il-13
Official title: {il-13}
C07K14/5437 (Il-13) appears on 145 US grants and 214 published applications in this corpus.
Search patents in C07K- Granted patents
- 145
- Published applications
- 214
- Assignees
- 90
- Inventors
- 273
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 6 | 0 |
| 1998 | 2 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 3 | 5 |
| 2003 | 4 | 14 |
| 2004 | 0 | 11 |
| 2005 | 4 | 11 |
| 2006 | 6 | 5 |
| 2007 | 8 | 7 |
| 2008 | 7 | 7 |
| 2009 | 3 | 7 |
| 2010 | 8 | 4 |
| 2011 | 4 | 9 |
| 2012 | 5 | 5 |
| 2013 | 4 | 4 |
| 2014 | 3 | 3 |
| 2015 | 6 | 9 |
| 2016 | 3 | 11 |
| 2017 | 6 | 8 |
| 2018 | 5 | 8 |
| 2019 | 9 | 8 |
| 2020 | 4 | 14 |
| 2021 | 5 | 12 |
| 2022 | 4 | 6 |
| 2023 | 6 | 12 |
| 2024 | 5 | 10 |
| 2025 | 12 | 11 |
| 2026 | 7 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,621 B2Massachusetts Institute of Technology
- Ligand discovery and gene delivery via retroviral surface display19 May 2026US 12,631,622 B2Massachusetts Institute of Technology
- IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy21 Apr 2026US 12,606,603 B2Seattle Children's Hospital
- IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof31 Mar 2026US 12,590,133 B2Medicenna Therapeutics Inc.
- Ligand discovery and gene delivery via retroviral surface display8 Oct 2026US 2026/0309700 A1Massachusetts Institute of Technology
- Multi-target drug conjugate and use thereof for cancer treatment1 Oct 2026US 2026/0295061 A1Virginia Tech Intellectual Properties, Inc.
- Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof1 Oct 2026US 2026/0297151 A1Medicenna Therapeutics Inc.
- Use of immunomodulation methods in combination with cytokine fusions for disease treatment13 Aug 2026US 2026/0232820 A1Medicenna Therapeutics Inc.
- Engineered t cell receptors and engineered immune cells expressing the same23 Jul 2026US 2026/0207748 A1Guangdong Tcrcure Biopharma Technology Co., Ltd.
Most cited
By later US patents
- Chimeric immunoreceptor useful in treating human gliomas170US 7,514,537 B2City of Hope · 2009
- Derivatives of growth hormone and related proteins160US 6,608,183 B1Bolder Biotechnology, Inc. · 2003
- Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells121US 8,822,647 B2City of Hope · 2014
- Chimeric immunoreceptor useful in treating human gliomas101US 8,324,353 B2City of Hope · 2012
- Alteration of Fc-fusion protein serum half-lives by mutagenesis84US 7,217,798 B2PDL BioPharma, Inc. · 2007